GlassScriptPhysician profile
Devika P Icecreamwala
NPI 1639444748
$27,432.02
in general payments reported to CMS, 2019-2025
23 companies · $1,845 in 2025
The $1,845 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,004 · 2020: $12K · 2021: $3,367 · 2022: $356 · 2023: $247 · 2024: $1,060 · 2025: $1,845.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,137 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,137.25 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $22,340.29 | 2019-2025 | |
| Abbvie INC. | $996.39 | 2021-2025 | |
| Allergan, INC. | $815.56 | 2019-2022 | |
| Genzyme Corporation | $539.68 | 2019-2025 | |
| Leo Pharma INC. | $481.30 | 2020-2025 | Adbry |
| Regeneron Healthcare Solutions, INC. | $357.83 | 2019-2025 | Dupixent, Libtayo |
| Strata Skin Sciences, INC. | $206.20 | 2024-2025 | Xtrac |
| Incyte Corporation | $201.58 | 2022-2025 | Opzelura |
| Galderma Laboratories, L.P. | $193.16 | 2019-2025 | Nemluvio |
| Merz North America, INC. | $188.90 | 2019-2021 | |
| Amgen INC. | $185.44 | 2024-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $167.91 | 2024-2025 | Sotyktu |
| Lilly USA, LLC | $139.41 | 2020-2025 | Taltz, Ebglyss |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $117.14 | 2019-2021 | |
| Arcutis Biotherapeutics, INC. | $116.98 | 2024-2025 | Zoryve |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $97.33 | 2024-2025 | Tremfya |
| Dermavant Sciences, INC. | $90.71 | 2023 | Vtama |
| Sun Pharmaceutical Industries INC. | $84.24 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $32.64 | 2025 | |
| Ucb, INC. | $26.75 | 2025 | Bimzelx |
| Almirall LLC | $21.47 | 2021 | |
| Dermira, INC. | $16.61 | 2019 | |
| Biofrontera INC. | $14.50 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devika Icecreamwala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.